Video

NK-Specific Strategies To Unlock Full Therapeutic Power

Source: Cell & Gene

In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, expert panelists Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, emphasized that natural killer (NK) cells require distinct, tailored activation methods to unlock their full therapeutic potential in cancer. They argued that unfair comparisons with T cells hinder innovation and highlighted how NK-focused engineering boosts both persistence and cytotoxicity.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)